Rare disease Background:
Background
Papillary thyroid cancer (PTC) is the most common type (80%) of thyroid cancer. Classic-PTC (c PTC) is the most common subtype of PTC followed by follicular variant of papillary thyroid cancer (FV-PTC). FV-PTC accounts for 10-20% of all PTC tumors and has 3 subtypes; completely encapsulated, wellcircumscribed, and infiltrative, the last being the most aggressive. FV-PTC has a follicular architecture in which follicles are lined by cells that have nuclear features of PTC. Crile and Hazard first described FV-PTC in 1953 [1] , which was later confirmed by Lindsay in 1960 [2] . Here, we report a case of bilateral renal metastases from FV-PTC found incidentally in a patient who presented with postmenopausal bleeding due to primary endometrial cancer. This is the first clinically detected case of FV-PTC with bilateral renal metastases reported in the English literature.
A B 
Case Report
A 70-year-old Guyanese woman presented in March of 2014 with complaints of occasional postmenopausal bleeding of 2 months duration. There was no history of hematuria, flank pain, weight loss, thyroid cancer, or thyroid surgery. Laboratory tests showed normal urine analysis, normal complete blood count, and basic metabolic panel. Endometrial biopsy showed endometrial complex glandular hyperplasia with atypia and focal well-differentiated adenocarcinoma, endometrioid type ( Figure 1) . A staging computerized tomography (CT) scan done in May 2014 revealed multiple bilateral lung nodules ( Figure 2A ) and bilateral soft tissue kidney masses ( Figure 2B ), with right mass measuring 5.6×2.7 cm and left mass measuring 6.4×5.5 cm. The right and left lobes of the thyroid gland were enlarged, with multiple calcific foci, consistent with multinodular goiter.
There was no evidence of significant adenopathy. No bone lesions were seen.
Presumptive diagnosis of primary renal cancer with lung metastases was considered. A positron emission tomography (PET) scan showed nonspecific findings of localized A B Figure 5A , 5B). Furthermore, we detected a new osteolytic lesion suspicious for metastasis at the base of the greater trochanter with SUVmax of 3.0 ( Figure 6A , 6B). PET scan also showed low-grade uptake localized to the endometrium [SUVmax: 4.5] . To confirm the origin of the tumor, a CT-guided lung biopsy was performed in July 2014. Pathology showed a well-differentiated adenocarcinoma ( Figure 7 ). Immunohistochemistry (IHC) staining was positive for cytokeratin 7 (CK 7) thyroid transcription factor-1 (TTF-1) and negative for CD 10, S 100, estrogen receptor (ER), and cancer antigen 125 (CA-125). The pathology and IHC profile were consistent with primary lung cancer.
The right femoral lytic lesion was biopsied in August 2014 to obtain more tissue for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) status for the possible use of Erlotinib; however, the results came back negative. Fluorescence in situ hybridization for ROS 1 was also negative, so Crizotinib could not be used. The IHC profile of bone biopsy further supported primary lung cancer (positive for CK 7, TTF-1 and negative for ER, CD 10, and CA 125).
A follow-up CT scan in October 2014 showed stable lung nodules and enlarging renal masses when compared to the prior CT scan. The CT findings and unchanged clinical performance status of the patient was now suggestive of bilateral renal cancer. The case was presented to the tumor board. The diagnosis was felt to be either lung carcinoma metastasizing to the kidney or a renal carcinoma metastasizing to the lung. Renal biopsy was recommended. The bone biopsy specimen, taken earlier, was also sent to Rosetta Genomics to assess tumor origin. The renal biopsy revealed papillary carcinoma with clear cell features, with morphology similar to that of the lung biopsy ( Figure 8 ). IHC staining was positive for CK 7, TTF-1 and negative for CK 20, CD10, CA 125, ER, and progesterone receptor (PR). The tumor showed diffuse (100%) nuclear staining for Paired box 8 (PAX-8) and TTF-1 ( Figure 9 ). While the histological features were not typical, the IHC profile was a better fit for thyroid carcinoma (as PAX-8 is extremely rare in lung carcinomas and renal cell carcinoma may show only focal staining for TTF-1). Additional immunostaining for thyroglobulin, napsin A (the lung marker), and carbonic anhydrase IX (the renal marker) to confirm the origin were recommended. The results from Rosetta Genomics came back revealing follicular thyroid cancer as the tumor of origin. The immunostaining was strongly positive for thyroglobulin ( Figure 10 ) and negative for napsin A and carbonic anhydrase IX. This confirmed the thyroid as the primary site.
A B
A B The plan was to perform left radical nephrectomy (as it was not iodine-avid, possibly due to necrosis) and hysterectomy. However, left radical nephrectomy was not performed due to the possible risk of deterioration of renal function, which had remained at baseline over the period of one and a half years. Hysterectomy was deferred since the patient had low-grade endometrial cancer with no further uterine bleeding. The revised treatment plan is to repeat the whole-body iodine scan in 3-6 months to assess the response to iodine ablation. The A B Figure 13 . A total body iodine-131 scan demonstrates severe, widespread iodine avid metastatic disease seen in the thyroid lungs (red arrow), right (blue arrow) and left (yellow arrow) kidney, lungs (white arrow) and greater trochanter (green arrow).
patient is being followed with thyroglobulin and thyroid-stimulating hormone (TSH) levels. The patient will also receive prophylactic radiation therapy for the right trochanteric lytic lesion.
Discussion
For certain malignancies, such as lung cancer, the kidney is not an uncommon site for metastases but for thyroid cancer it is extremely rare. Bracken et al., in an autopsy study of 11 328 patients who died of malignant disease, reported that 816 (7.2%) had renal metastases. Out of all the cases of renal metastases, melanoma was the most common primary (35.5%) site followed by lung (17.8%), gastrointestinal tract (11.5%), genitourinary tract (10.5%), breast (8.3%), and gynecologic tract (4.3%) [3] . Thyroid cancer metastasizing to the kidney is rare and only 24 cases have been reported so far in the English literature. Out of these, 6 were FV-PTC, and this is the 7 th case of FV-PTC (Table 1 ). The clinical manifestations of these tumors were palpable abdominal mass, abdominal/flank pain, or hematuria, with only 2 cases detected incidentally, including the present case. This is the first reported case of FV-PTC with bilateral renal metastases. In the present case there was no history of thyroid cancer, thyroid surgery, or radiation exposure, in contrast to other reported cases of FV-PTC.
The most frequent distant sites of thyroid metastases are the lungs and bones, but metastases to the kidney are very rare and most often are detected during autopsy. In a study of 161 autopsy cases of metastatic thyroid cancer, 6.1% of well-differentiated thyroid cancer metastasized to the kidney [10] .
There are many possible reasons for poor detection of renal metastasis. It may be due to the inability of the metastatic lesions to trap iodide on iodine-131 scan, secondary to misdirected, altered, or intracellularly entrapped sodium iodide symporter (NIS) protein. NIS, a transmembrane glycoprotein, mediates uptake of iodide into the follicular cells of the thyroid gland in the synthesis of thyroid hormone [7] . Other possible reasons are: inability of the magnetic resonance imaging (MRI) to differentiate between the renal metastases and solid kidney tumors (since metastatic lesions usually appear isointense with surrounding tissue on T1-weighted images of MRI) [11] ; misinterpretation of iodine-131 scan in the abdomen as physiological uptake [7] ; and low diagnostic yield of routine imaging modalities such as CT or US [12] . Moreover, metastases to the kidney occur very late due to the indolent nature of thyroid cancer. Often these metastases do not produce any signs or symptoms. One case had metastases 37 years after the diagnosis of thyroid cancer [13] .
The diagnosis of FV-PTC depends on characteristic nuclear features of papillary carcinoma, even when there is no extension beyond the thyroid gland [2] . FV-PTC is difficult to diagnosis clinically and pathologically because most it usually occurs in the background of nodular goiter, giving the false impression of follicular adenoma or adenomatoid nodule. Furthermore, FVPTC sometimes does not possess all of the characteristic nuclear features, or these may be present only focally, while the rest of the tumor exhibits benign features [1] . Additionally, there is an overlap of histologic features between FV-PTC and other follicular neoplasms. It has been reported that FNAB has a low sensitivity for diagnosing FVPTC, therefore requiring thyroidectomy for accurate diagnosis [14] .
To clearly identify the primary neoplasm, immunohistochemistry plays an important role. One marker may be positive for more than 1 tumor, and thus a combination of markers is needed to confirm the diagnosis. The CK7, CK20, and TTF-1 are important IHC markers for the diagnosis of lung tumors and are useful to differentiate primary pulmonary adenocarcinomas from metastatic adenocarcinomas to the lung [15] . TTF-1 is found in the lung and the thyroid gland but is negative in renal tumors [16] . PAX8 is a highly sensitive marker for thyroid cancer and renal tumors, but it is not found in lung adenocarcinoma [17] . Thyroglobulin is a sensitive and specific histogenetic marker for follicular cell-derived thyroid carcinomas [18] .
Surgery offers a favorable prognosis for FV-PTC. It has been reported recently that encapsulated FV-PTC and infiltrative FV-PTC demonstrate clinical behavior similar to follicular adenoma and classic PTC, respectively ( Figure 14) , and should be treated similarly [19] . The best treatment approach to metastatic differentiated thyroid cancer is the surgical removal of the thyroid gland and metastatic lesions followed by iodine-131 ablation therapy. Whole-body scintigraphy should be performed in high-risk cases, especially in patients with elevated thyroglobulin levels. Patients should be given thyroxin suppression therapy following surgical treatment [1] . Mortality in FV-PTC related to distant metastases was 67% in a clinicopathological study done by Mizukami et al. [20] .
Conclusions
This case adds to the rare reports in the literature of FV-PTC metastasizing to kidneys. The presence of pulmonary nodules and kidney masses do not always suggest the lung or the kidney as primary tumor sites. The clinician should be aware of the possibility of metastases and look for the primary source, which in the present case was the thyroid. The possibility of thyroid cancer gets overlooked since it rarely metastasizes to the kidneys, so clinicians should have a high index of suspicion even if there is no history of thyroid cancer or thyroid surgery. In patients with metastatic disease, immunohistochemistry plays an important role in determining the primary site of origin since it may have a major impact on therapy and prognosis. It is important to note that in case of multiple organ metastases, each metastatic lesion should be biopsied for definitive diagnosis and appropriate treatment. Since FNAB has a low sensitivity for diagnosing FVPTC, accurate diagnosis requires thyroidectomy.
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